Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice

被引:18
作者
Kalvass, JC [1 ]
Graff, CL [1 ]
Pollack, GM [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA
关键词
antinociception; CF-1; mice; P-glycoprotein; phenotyping; loperamide;
D O I
10.1023/B:PHAM.0000045241.26925.8b
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. A subpopulation of the CF-1 mouse strain ( approximately 25%) lacks P-gp expression, and consequently, increased brain penetration of many substrates is observed in these animals. Mice lacking the mdr1a gene represent an important research tool to study the potential effects of P-gp on CNS substrate disposition. Methods. Adult CF-1 mice were used in all experiments. Loperamide-induced antinociception was determined by the hotplate latency test at 0.25, 2, and 4 h post-dose. At the conclusion of the pharmacodynamic experiment(s), trunk blood and brain tissue were collected and analyzed by high-performance liquid chromatography-mass spectrometry (LC-MS/MS). Mice were also genotyped for their mdr1a status via RT-PCR. Results. All mice with three consecutive effects of maximum hotplate latency (60 s) showed considerable opioid-like behavior in addition to antinociception. Mice without three consecutive effects of maximum hotplate latency (less than or equal to30 s) showed no opioid-like behavior. The loperamide brain-to-serum ratio in mice identified as P-gp-deficient was 65-fold higher compared to the P-gp-competent animals (10.1 +/- 1.0 vs. 0.155 +/- 0.018). All animals identified as phenotypically P-gp competent based on the hotplate assay evidenced the mdr1a(+/+) genotype. Conclusion. This assay appears to offer a rapid and unambiguous measure via a relatively non-invasive, simple technique to identify P-gp status in the CF-1 subpopulation of mice.
引用
收藏
页码:1867 / 1870
页数:4
相关论文
共 15 条
[1]   CLASSICAL AND NOVEL FORMS OF MULTIDRUG-RESISTANCE AND THE PHYSIOLOGICAL FUNCTIONS OF P-GLYCOPROTEINS IN MAMMALS [J].
BORST, P ;
SCHINKEL, AH ;
SMIT, JJM ;
WAGENAAR, E ;
VANDEEMTER, L ;
SMITH, AJ ;
EIJDEMS, EWHM ;
BAAS, F ;
ZAMAN, GJR .
PHARMACOLOGY & THERAPEUTICS, 1993, 60 (02) :289-299
[2]  
Chen CP, 1997, J PHARMACOL EXP THER, V283, P1151
[3]   Blood-brain barrier efflux transport [J].
Golden, PL ;
Pollack, GM .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (09) :1739-1753
[4]   SURFACE GLYCOPROTEIN MODULATING DRUG PERMEABILITY IN CHINESE-HAMSTER OVARY CELL MUTANTS [J].
JULIANO, RL ;
LING, V .
BIOCHIMICA ET BIOPHYSICA ACTA, 1976, 455 (01) :152-162
[5]   P-GLYCOPROTEIN - MULTIDRUG-RESISTANCE AND A SUPERFAMILY OF MEMBRANE-ASSOCIATED TRANSPORT PROTEINS [J].
JURANKA, PF ;
ZASTAWNY, RL ;
LING, V .
FASEB JOURNAL, 1989, 3 (14) :2583-2592
[6]   P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity [J].
Lankas, GR ;
Cartwright, ME ;
Umbenhauer, D .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 143 (02) :357-365
[7]   Multidrug resistance: Molecular mechanisms and clinical relevance [J].
Ling, V .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (Suppl 1) :S3-S8
[8]   ANTAGONISM OF THE MORPHINE-INDUCED STRAUB TAIL REACTION BY KAPPA-OPIOID RECEPTOR ACTIVATION IN MICE [J].
NARITA, M ;
SUZUKI, T ;
MISAWA, M ;
NAGASE, H .
PSYCHOPHARMACOLOGY, 1993, 110 (1-2) :254-256
[9]   No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects [J].
Pauli-Magnus, C ;
Feiner, J ;
Brett, C ;
Lin, E ;
Kroetz, DL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) :487-498
[10]   The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene [J].
Pippert, TR ;
Umbenhauer, DR .
JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2001, 15 (02) :83-89